These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24051074)

  • 1. Conformational restriction approach to β-secretase (BACE1) inhibitors III: effective investigation of the binding mode by combinational use of X-ray analysis, isothermal titration calorimetry and theoretical calculations.
    Yonezawa S; Fujiwara K; Yamamoto T; Hattori K; Yamakawa H; Muto C; Hosono M; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
    Bioorg Med Chem; 2013 Nov; 21(21):6506-22. PubMed ID: 24051074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational restriction approach to β-secretase (BACE1) inhibitors: effect of a cyclopropane ring to induce an alternative binding mode.
    Yonezawa S; Yamamoto T; Yamakawa H; Muto C; Hosono M; Hattori K; Higashino K; Yutsudo T; Iwamoto H; Kondo Y; Sakagami M; Togame H; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
    J Med Chem; 2012 Oct; 55(20):8838-58. PubMed ID: 22998419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BACE1 inhibitors: a head group scan on a series of amides.
    Woltering TJ; Wostl W; Hilpert H; Rogers-Evans M; Pinard E; Mayweg A; Göbel M; Banner DW; Benz J; Travagli M; Pollastrini M; Marconi G; Gabellieri E; Guba W; Mauser H; Andreini M; Jacobsen H; Power E; Narquizian R
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4239-43. PubMed ID: 23735744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
    Chakraborty S; Kumar S; Basu S
    Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational restriction approach to BACE1 inhibitors II: SAR study of the isocytosine derivatives fixed with a cis-cyclopropane ring.
    Yonezawa S; Yamakawa H; Muto C; Hosono M; Yamamoto T; Hattori K; Sakagami M; Togame H; Tanaka Y; Nakano T; Takemoto H; Arisawa M; Shuto S
    Bioorg Med Chem Lett; 2013 May; 23(10):2912-5. PubMed ID: 23562056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbazole-containing arylcarboxamides as BACE1 inhibitors.
    Bertini S; Asso V; Ghilardi E; Granchi C; Manera C; Minutolo F; Saccomanni G; Bortolato A; Mason J; Moro S; Macchia M
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6657-61. PubMed ID: 21986588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(2-(Piperazin-1-yl)phenyl)arylamide Derivatives as β-Secretase (BACE1) Inhibitors: Simple Synthesis by Ugi Four-Component Reaction and Biological Evaluation.
    Edraki N; Firuzi O; Fatahi Y; Mahdavi M; Asadi M; Emami S; Divsalar K; Miri R; Iraji A; Khoshneviszadeh M; Firoozpour L; Shafiee A; Foroumadi A
    Arch Pharm (Weinheim); 2015 May; 348(5):330-7. PubMed ID: 25787800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization.
    Cumming J; Babu S; Huang Y; Carrol C; Chen X; Favreau L; Greenlee W; Guo T; Kennedy M; Kuvelkar R; Le T; Li G; McHugh N; Orth P; Ozgur L; Parker E; Saionz K; Stamford A; Strickland C; Tadesse D; Voigt J; Zhang L; Zhang Q
    Bioorg Med Chem Lett; 2010 May; 20(9):2837-42. PubMed ID: 20347593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.
    Suzuki K; Hamada Y; Nguyen JT; Kiso Y
    Bioorg Med Chem; 2013 Nov; 21(21):6665-73. PubMed ID: 23993670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment-based discovery of BACE1 inhibitors using functional assays.
    Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J
    Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From AChE to BACE1 inhibitors: The role of the amine on the indanone scaffold.
    Rampa A; Mancini F; De Simone A; Falchi F; Belluti F; Di Martino RM; Gobbi S; Andrisano V; Tarozzi A; Bartolini M; Cavalli A; Bisi A
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2804-8. PubMed ID: 26003339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Efficient Enzyme Production and Structure-Based Discovery Platform for BACE1 Inhibitors.
    Yen YC; Kammeyer AM; Jensen KC; Tirlangi J; Ghosh AK; Mesecar AD
    Biochemistry; 2019 Nov; 58(44):4424-4435. PubMed ID: 31549827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
    Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
    J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
    Winneroski LL; Erickson JA; Green SJ; Lopez JE; Stout SL; Porter WJ; Timm DE; Audia JE; Barberis M; Beck JP; Boggs LN; Borders AR; Boyer RD; Brier RA; Hembre EJ; Hendle J; Garcia-Losada P; Minguez JM; Mathes BM; May PC; Monk SA; Rankovic Z; Shi Y; Watson BM; Yang Z; Mergott DJ
    Bioorg Med Chem; 2020 Jan; 28(1):115194. PubMed ID: 31786008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
    Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds.
    Piazzi L; Cavalli A; Colizzi F; Belluti F; Bartolini M; Mancini F; Recanatini M; Andrisano V; Rampa A
    Bioorg Med Chem Lett; 2008 Jan; 18(1):423-6. PubMed ID: 17998161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors.
    Liu J; Chen W; Xu Y; Ren S; Zhang W; Li Y
    Bioorg Med Chem; 2015 May; 23(9):1963-74. PubMed ID: 25842365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
    Narang SS; Goyal D; Goyal B
    Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
    Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.